Maayani S, Weinstein H
Prog Clin Biol Res. 1979;27:91-106.
Phencylidine derivatives exhibit multiple interactions with cholinergic systems: they block nicotinic and muscarinic receptors,and inhibit both acetyl and butyrylcholinesterase. In peripheral tissue, the net pharmacological effects of the phencyclidines is antiacetylcholine activity. The dissociation constants measured in isolated smooth muscle and from competition experiments for the muscarinic high-affinity binding sites in brain homogenates (Kd = 10(-5) - 10(-6) M) are 3--4 orders of magnitude lower than those of anticholinergic glycolate esters. However, phencyclidines have comparable potency to that of d-tubocurarine in blocking the nicotinic receptor in the isolated frog rectus abdominis (Kd = 10(-6) M). Brain uptake experiments of (3H) labeled phencyclidine showed that during the time period in which central effects are observed with these drugs their concentration in brain reaches values close to the Kd (10(-5) - 10(-6) M). This finding, and the cross tolerance observed in vivo between phencyclidine and other centrally acting cholinergic drugs supports the possible involvement of cholinergic interactions in the psychotropic action of phenyclidine derivatives. Quantum chemical calculations of the interaction pharmacophores of drugs in the phencyclidine series have indicated the molecular determinants for the interaction of these drugs with the muscarinic receptor. The calculations revealed that these drugs can match the reactivity characteristics of ACh and the semi-rigid muscarinic agonist 3-acetoxyquinuclidine, but their rigid molecular frame will be conductive to antagonistic rather than agonistic activity when the drug-receptor complex is formed. The identification of a "cholinergic interaction pharmacophore" for these drugs by quantum mechanical calculations made possible the suggestion of other active phencyclidine derivatives, e.g. p-NH2 and p-OH analogs which proved to be equipotent to phencyclidine. The inactivity of the p-NO2 derivative was also predicted on this basis and served as an additional confirmation of the theoretical criterion for activity; the difference between the activities of the ethynyl and cyano derivatives was explained by the modification of the cholinergic interaction pharmacophore. On the basis of these theoretical predictions, electrophysiological studies were carried out by the others and the results prompted the suggestion that "physostigmine is of potential value in the treatment of post-operative patients emerging from ketamine anesthesia and in the treatment of phencyclidine overdosed patients".
它们可阻断烟碱型和毒蕈碱型受体,并抑制乙酰胆碱酯酶和丁酰胆碱酯酶。在周围组织中,苯环利定的净药理作用是抗乙酰胆碱活性。在离体平滑肌中测得的解离常数以及在脑匀浆中毒蕈碱高亲和力结合位点的竞争实验(Kd = 10^(-5) - 10^(-6) M)表明,其解离常数比抗胆碱能乙醇酸酯低3 - 4个数量级。然而,在离体青蛙腹直肌中,苯环利定阻断烟碱型受体的效力与筒箭毒碱相当(Kd = 10^(-6) M)。用(3H)标记的苯环利定进行的脑摄取实验表明,在观察到这些药物产生中枢效应的时间段内,它们在脑中的浓度达到接近Kd(10^(-5) - 10^(-6) M)的值。这一发现以及在体内观察到的苯环利定与其他中枢作用胆碱能药物之间的交叉耐受性,支持了胆碱能相互作用可能参与苯环利定衍生物精神作用的观点。对苯环利定系列药物相互作用药效基团的量子化学计算表明了这些药物与毒蕈碱型受体相互作用的分子决定因素。计算结果显示,这些药物可以匹配乙酰胆碱和半刚性毒蕈碱激动剂3 - 乙酰氧基奎宁环的反应特性,但当形成药物 - 受体复合物时,它们的刚性分子框架将有利于拮抗活性而非激动活性。通过量子力学计算确定这些药物的“胆碱能相互作用药效基团”,使得能够提出其他活性苯环利定衍生物,例如对氨基和对羟基类似物,它们被证明与苯环利定等效。在此基础上还预测了对硝基衍生物的无活性,并作为活性理论标准的额外证实;乙炔基和氰基衍生物活性的差异通过胆碱能相互作用药效基团的修饰得到了解释。基于这些理论预测,其他人进行了电生理研究,结果提示“毒扁豆碱在治疗氯胺酮麻醉后苏醒的术后患者以及苯环利定过量患者方面具有潜在价值”。